cbdMD posted fiscal Q3 net sales of $5.6 million, up 20% year over year, driven by a 61% wholesale jump.
Operating loss widened to $1.13 million; net loss attributable to common shareholders was $1.2 million, or $0.11 per share.
Gross margin fell 6.8 percentage points to 54.7% on mix shift to wholesale, added warehousing/repacking, and higher inventory reserves tied to regulatory changes.
Oasis distributor depletions rose 25% in the quarter; Bluebird Botanicals added more than $0.5 million in its first full-quarter contribution.
Management cited July cost cuts targeting $100,000-$150,000 in monthly savings, alongside one-time M&A diligence and legal costs.
YCBD•
